Citations (98)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Lars Henningsohn, Suzanne Kilany, Maja Svensson & Judith L. Jacobsen. (2017) Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study. The Aging Male 20:4, pages 266-276.
Read now
Read now
Damla Erginturk Acar, Ugur Acar, Ozdemir Ozdemir, Zuhal Ozen Tunay & Sabri Cavkaytar. (2016) The short-term and long-term adverse ocular effects of fesoterodine fumarate. Cutaneous and Ocular Toxicology 35:3, pages 181-184.
Read now
Read now
Ariana L. Smith & Alan J. Wein. (2011) Urinary incontinence—pharmacotherapy options. Annals of Medicine 43:6, pages 461-476.
Read now
Read now
Tola Omotosho & Chi Chiung Grace Chen. (2010) Update on tolterodine extended-release for treatment of overactive bladder. Open Access Journal of Urology 2, pages 185-191.
Read now
Read now
Kylie J Mansfield. (2010) Role of fesoterodine in the treatment of overactive bladder. Open Access Journal of Urology 2, pages 1-9.
Read now
Read now
Emilio Sacco, Daniele Tienforti, Alessandro D’Addessi, Francesco Pinto, Marco Racioppi, Angelo Totaro, Daniele D’Agostino, Francesco Marangi & Pierfrancesco Bassi. (2010) Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access Journal of Urology 2, pages 11-24.
Read now
Read now
Scott R. Serels, Marc R. Toglia, Sergio Forero-Schwanhaeuser & Weizhong He. (2010) Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Current Medical Research and Opinion 26:10, pages 2277-2285.
Read now
Read now
Doreen E Chung & Alexis E Te. (2009) Tolterodine extended-release for overactive bladder. Expert Opinion on Pharmacotherapy 10:13, pages 2181-2194.
Read now
Read now
Stefano Salvatore, Maurizio Serati & Pierfrancesco Bolis. (2008) Tolterodine for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 9:7, pages 1249-1255.
Read now
Read now
Dudley Robinson & Linda Cardozo. (2008) Pharmacotherapy of overactive bladder syndrome. Expert Review of Clinical Pharmacology 1:1, pages 163-175.
Read now
Read now
Veronica Mallett, David Burks, Alan D. Garely & Neila Smith. (2007) Solifenacin treatment for overactive bladder in black patients: patient-reported symptom bother and health-related quality of life outcomes. Current Medical Research and Opinion 23:4, pages 821-831.
Read now
Read now
Sum Lam & Olga Hilas. (2007) Pharmacologic management of overactive bladder. Clinical Interventions in Aging 2:3, pages 337-345.
Read now
Read now
Atul Tiwari & Krishna S Naruganahalli. (2006) Current and emerging investigational medical therapies for the treatment of overactive bladder. Expert Opinion on Investigational Drugs 15:9, pages 1017-1037.
Read now
Read now
Arun Sahai, Mohammed Shamim Khan, Manit Arya, Jason John, Rajinder Singh & Hitendra RH Patel. (2006) The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. Expert Opinion on Pharmacotherapy 7:5, pages 509-527.
Read now
Read now
R. J. Millard & M. Halaska. (2006) Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Current Medical Research and Opinion 22:1, pages 41-48.
Read now
Read now
Eric S Rovner. (2005) Tolterodine for the treatment of overactive bladder: a review. Expert Opinion on Pharmacotherapy 6:4, pages 653-666.
Read now
Read now
Nicole
M. Rogalski. (2005) A GRADUATE NURSING CURRICULUM FOR THE EVALUATION AND MANAGEMENT OF URINARY INCONTINENCE. Educational Gerontology 31:2, pages 139-159.
Read now
Read now
Yoram Abramov & Peter K Sand. (2004) Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. Expert Opinion on Pharmacotherapy 5:11, pages 2351-2359.
Read now
Read now
Lars Viktrup & Richard C. Bump. (2003) Pharmacological agents used for the treatment of stress urinary incontinence in women. Current Medical Research and Opinion 19:6, pages 485-490.
Read now
Read now
Articles from other publishers (79)
BaoLing Chen, Wanlin Yang, Yuqi Luo, Eng-King Tan & Qing Wang. (2023) Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions. Journal of Neurology.
Crossref
Crossref
Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein & Karl-Erik Andersson. (2023) Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews 75:4, pages 554-674.
Crossref
Crossref
Paswach Wiriyakijja, Sven Eric Niklander, Alan Roger Santos-Silva, Michal Kuten Shorrer, Melanie Louise Simms, Alessandro Villa, Vidya Sankar, Alexander Ross Kerr, Richeal Ni Riordain, Siri Beier Jensen & Konstantina Delli. (2023) World Workshop on Oral Medicine VIII: development of a core outcome set for dry mouth: A systematic review of outcome domains for xerostomia. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.
Crossref
Crossref
Ariana L. Smith & Alan J. Wein. 2019. Contemporary Pharmacotherapy of Overactive Bladder. Contemporary Pharmacotherapy of Overactive Bladder
85
113
.
Roxana Geoffrion. (2018) N o 283-Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie. Journal of Obstetrics and Gynaecology Canada 40:1, pages e33-e44.
Crossref
Crossref
Roxana Geoffrion. (2018) No. 283-Treatments for Overactive Bladder: Focus on Pharmacotherapy. Journal of Obstetrics and Gynaecology Canada 40:1, pages e22-e32.
Crossref
Crossref
Ji-Yeong Byeon, Young-Hoon Kim, Se-Hyung Kim, Choong-Min Lee, Chang-Ik Choi, Jung-Woo Bae, Choon-Gon Jang, Seok-Yong Lee & Yun Jeong Lee. (2017) Inhibition of salivary secretion by tolterodine transdermal patch. Archives of Pharmacal Research 40:12, pages 1455-1463.
Crossref
Crossref
P. Abrams, C. Kelleher, D. Staskin, R. Kay, A. Martan, I. Mincik, D. Newgreen, A. Ridder, A. Paireddy & R. van Maanen. (2016) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World Journal of Urology 35:5, pages 827-838.
Crossref
Crossref
Roxana Geoffrion. (2016) Traitements visant la vessie hyperactive : Accent sur la pharmacothérapie. Journal of Obstetrics and Gynaecology Canada 38:12, pages S158-S170.
Crossref
Crossref
Jose Carlos Truzzi, Cristiano Mendes Gomes, Carlos A. Bezerra, Ivan Mauricio Plata, Jose Campos, Gustavo Luis Garrido, Fernando G. Almeida, Marcio Augusto Averbeck, Alexandre Fornari, Anibal Salazar, Arturo Dell’Oro, Caio Cintra, Carlos Alberto Ricetto Sacomani, Juan Pablo Tapia, Eduardo Brambila, Emilio Miguel Longo, Flavio Trigo Rocha, Francisco Coutinho, Gabriel Favre, José Antonio Garcia, Juan Castaño, Miguel Reyes, Rodrigo Eugenio Leyton, Ruiter Silva Ferreira, Sergio Duran, Vanda López & Ricardo Reges. (2016) Overactive bladder – 18 years – Part II. International braz j urol 42:2, pages 199-214.
Crossref
Crossref
Satoru TAKAHASHI, Mineo TAKEI, Osamu NISHIZAWA, Osamu YAMAGUCHI, Kumiko KATO, Momokazu GOTOH, Yasukuni YOSHIMURA, Masami TAKEYAMA, Hideo OZAWA, Makoto SHIMADA, Tomonori YAMANISHI, Masaki YOSHIDA, Hikaru TOMOE, Osamu YOKOYAMA & Masayasu KOYAMA. (2016) Clinical Guideline for Female Lower Urinary Tract Symptoms. LUTS: Lower Urinary Tract Symptoms 8:1, pages 5-29.
Crossref
Crossref
W. Stuart Reynolds, Melissa McPheeters, Jeffery Blume, Tanya Surawicz, Katherine Worley, Li Wang & Katherine Hartmann. (2015) Comparative Effectiveness of Anticholinergic Therapy for Overactive Bladder in Women. Obstetrics & Gynecology 125:6, pages 1423-1432.
Crossref
Crossref
. 2015. Evidence-Based Physical Therapy for the Pelvic Floor. Evidence-Based Physical Therapy for the Pelvic Floor
131
270
.
Kristian Winge. 2015. Neurology of Sexual and Bladder Disorders. Neurology of Sexual and Bladder Disorders
335
356
.
W. Gibson, A. Athanasopoulos, H. Goldman, H. Madersbacher, D. Newman, J. Spinks, J. J. Wyndaele & A. Wagg. (2014) Are we shortchanging frail older people when it comes to the pharmacological treatment of urgency urinary incontinence?. International Journal of Clinical Practice 68:9, pages 1165-1173.
Crossref
Crossref
Karl-Erik Andersson. 2014. Bladder Dysfunction in the Adult. Bladder Dysfunction in the Adult
121
222
.
Sona Kapoor, Andreas Bourdoumis, Lewis Mambu & Jayanta Barua. (2013)
Effective management of lower urinary tract dysfunction in idiopathic
P
arkinson's disease
. International Journal of Urology 20:1, pages 79-84.
Crossref
Crossref
Roxana Geoffrion, Danny Lovatsis, Jens-Erik Walter, Queena Chou, William Easton, Annette Epp, Roxana Geoffrion, Marie-Andrée Harvey, Annick Larochelle, Kenny Maslow, Grace Neustaedter, Dante Pascali, Marianne Pierce, Jane A. Schulz, Vyta Senikas & David Wilkie. (2012) Treatments for Overactive Bladder: Focus on Pharmacotherapy. Journal of Obstetrics and Gynaecology Canada 34:11, pages 1092-1101.
Crossref
Crossref
Philip E. V. Van Kerrebroeck. (2012) Does Conservative Management Really Benefit Patients with OAB?. Current Urology Reports 13:5, pages 348-355.
Crossref
Crossref
Olufenwa Famakinwa, Charles Chang & Doreen E. Chung. (2011) Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder. Current Bladder Dysfunction Reports 7:1, pages 40-50.
Crossref
Crossref
Altaf Mangera & Christopher R. Chapple. (2011) Summary of Anticholinergic Pharmacotherapy Available for Overactive Bladder Dysfunction. Current Bladder Dysfunction Reports 7:1, pages 51-58.
Crossref
Crossref
Priya Madhuvrata, June D Cody, Gaye Ellis, G Peter Herbison & E. Jean C Hay-Smith. (2012) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Oussama El Yazami AdliJacques Corcos. (2012) Clinical Use of Tolterodine Extended Release in Overactive Bladder. Clinical Medicine Insights: Urology 6, pages CMU.S6425.
Crossref
Crossref
Karl-Erik Andersson & Alan J. Wein. 2012. Campbell-Walsh Urology. Campbell-Walsh Urology
1967
2002.e14
.
Emilio Sacco, Riccardo Bientinesi, Francesco Marangi, Alessandro D'addessi, Marco Racioppi, Gaetano Gulino, Francesco Pinto, Angelo Totaro & Pierfrancesco Bassi. (2011) Overactive Bladder Syndrome: The Social and Economic Perspective. Urologia Journal 78:4, pages 241-256.
Crossref
Crossref
C. C. Sexton, S. M. Notte, C. Maroulis, R. R. Dmochowski, L. Cardozo, D. Subramanian & K. S. Coyne. (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. International Journal of Clinical Practice 65:5, pages 567-585.
Crossref
Crossref
Maria Tzefos, Christian Dolder & Jacqueline L Olin. (2009) Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder. Annals of Pharmacotherapy 43:12, pages 1992-2000.
Crossref
Crossref
T. L. Griebling, S. R. Kraus, H. E. Richter, D. B. Glasser & M. Carlsson. (2009) Tolterodine extended release is well tolerated in older subjects. International Journal of Clinical Practice 63:8, pages 1198-1204.
Crossref
Crossref
Helmut Madersbacher, Gerd Mürtz, Schahnaz Alloussi, Burghard Domurath, Thomas Henne, Iris Körner, Andreas Niedeggen, Joseph Nounla, Jürgen Pannek, Heinrich Schulte-Baukloh, Daniela Schultz-Lampel, Paul Bock & Gerhard Strugala. (2009) Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. BJU International 103:6, pages 776-781.
Crossref
Crossref
Osamu Yamaguchi, Osamu Nishizawa, Masayuki Takeda, Osamu Yokoyama, Yukio Homma, Hidehiro Kakizaki, Kenji Obara, Momokazu Gotoh, Yasuhiko Igawa, Naarihito Seki & Masaki Yoshida. (2009) Clinical guidelines for overactive bladder. International Journal of Urology 16:2, pages 126-142.
Crossref
Crossref
Helen Blackett, Richard Walker & Brian Wood. (2009) Urinary dysfunction in Parkinson's disease: A review. Parkinsonism & Related Disorders 15:2, pages 81-87.
Crossref
Crossref
Steven E. Swift, Paul Siami & Sergio Forero-Schwanhaeuser. (2009) Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment. Clinical Drug Investigation 29:5, pages 305-316.
Crossref
Crossref
Khanh Tran, Robert M. Levin & Shaker A. Mousa. (2009) Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. Advances in Urology 2009, pages 1-10.
Crossref
Crossref
Alan J. Wein, Rajiv Saini & David R. Staskin. 2009. Pharmacology and Therapeutics. Pharmacology and Therapeutics
445
456
.
Daniel H. Biller & G. Willy Davila. 2009. Pelvic Floor Dysfunction. Pelvic Floor Dysfunction
169
174
.
Martin C. Michel. 2009. Continence. Continence
191
201
.
Giacomo Novara, Antonio Galfano, Silvia Secco, Carolina D'Elia, Stefano Cavalleri, Vincenzo Ficarra & Walter Artibani. (2008) A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder. European Urology 54:4, pages 740-764.
Crossref
Crossref
Michael B. Chancellor, Norman Zinner, Kristene Whitmore, Kathleen Kobashi, Jeffrey A. Snyder, Paul Siami, Mickey Karram, Christine Laramée, James P. Capo'Jr.Jr., Raafat Seifeldin, Sergio Forero-Schwanhaeuser & Indrani Nandy. (2008) Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. Clinical Therapeutics 30:10, pages 1766-1781.
Crossref
Crossref
Steven D. Kleeman & Mickey M. Karram. 2008. Uroginecología y cirugía reconstructiva de la pelvis. Uroginecología y cirugía reconstructiva de la pelvis
363
385
.
Alan J. Wein & M. Louis Moy. 2008. Female Urology. Female Urology
233
256
.
Sushma Srikrishna, Dudley Robinson, Linda Cardozo & Maria Vella. (2007) Management of overactive bladder syndrome. Postgraduate Medical Journal 83:981, pages 481-486.
Crossref
Crossref
Linda Cardozo. (2007) The overactive bladder syndrome: treating patients on an individual basis. BJU International 99:s3, pages 1-7.
Crossref
Crossref
Philip Toozs-Hobson & Pallavi Latthe. (2007) Critical Evaluation of the Efficacy and Safety of Anticholinergics in Overactive Bladder. European Urology Supplements 6:5, pages 425-431.
Crossref
Crossref
Laura M. Bogart, Sandra H. Berry & J. Quentin Clemens. (2007) Symptoms of Interstitial Cystitis, Painful Bladder Syndrome and Similar Diseases in Women: A Systematic Review. Journal of Urology 177:2, pages 450-456.
Crossref
Crossref
. 2007. Evidence-Based Physical Therapy for the Pelvic Floor. Evidence-Based Physical Therapy for the Pelvic Floor
161
315
.
Steven D. Kleeman & Mickey M. Karram. 2007. Urogynecology and Reconstructive Pelvic Surgery. Urogynecology and Reconstructive Pelvic Surgery
353
376
.
Alan S. Braverman, Brett Lebed, Mitchell Linder & Michael R. Ruggieri. (2006)
M
2
mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors
. Neurourology and Urodynamics 26:1, pages 63-70.
Crossref
Crossref
Jamie A. Kanofsky & Victor W. Nitti. (2006) Tolterodine for Treatment of Overactive Bladder. Urologic Clinics of North America 33:4, pages 447-453.
Crossref
Crossref
Alan D. Garely, Joel M. Kaufman, Peter K. Sand, Neila Smith & Masakazu Andoh. (2006) Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: The VESIcare open-label trial (VOLT). Clinical Therapeutics 28:11, pages 1935-1946.
Crossref
Crossref
Roger R. Dmochowski. (2006) The puzzle of overactive bladder: controversies, inconsistencies, and insights. International Urogynecology Journal 17:6, pages 650-658.
Crossref
Crossref
Roger R. Dmochowski, Jonathan S. Starkman & G. Willy Davila. (2006) Transdermal drug delivery treatment for overactive bladder. International braz j urol 32:5, pages 513-520.
Crossref
Crossref
Kristian Winge & Clare J. Fowler. (2006) Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Movement Disorders 21:6, pages 737-745.
Crossref
Crossref
VICTOR W. NITTI, ROGER DMOCHOWSKI, RODNEY A. APPELL, JOSEPH T. WANG, TAMARA BAVENDAM & ZHONGHONG GUAN. (2006) Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU International 97:6, pages 1262-1266.
Crossref
Crossref
Dudley RobinsonLinda Cardozo. (2016) Pharmacological Treatment for Overactive Bladder in Women. Women's Health 2:2, pages 239-250.
Crossref
Crossref
Daniel H. Biller & G. Willy Davila. 2006. Pelvic Floor Dysfunction. Pelvic Floor Dysfunction
169
174
.
Stephen J. Griffin & William H. Turner. 2006. Drug Treatment in Urology. Drug Treatment in Urology
1
20
.
Hashim Hashim & Paul Abrams. (2005) Treatment of overactive bladder syndrome and detrusor overactivity. Reviews in Gynaecological Practice 5:4, pages 243-250.
Crossref
Crossref
Hashim Hashim & Paul Abrams. (2005) Treatment options for the overactive bladder syndrome. Therapy 2:6, pages 921-936.
Crossref
Crossref
Hashim Hashim & Paul Abrams. (2005) Treatment options for the overactive bladder syndrome. Therapy 2:6, pages 921-936.
Crossref
Crossref
Tam H Le, Donald R Ostergard, Narender N Bhatia & Melissa E Huggins. (2005) Newer pharmacologic options in management of overactive bladder syndrome. Current Opinion in Obstetrics & Gynecology 17:5, pages 495-506.
Crossref
Crossref
Victor W. Nitti. (2005) Surgical treatment of stress urinary incontinence in women: is “clinical effectiveness” a valid concept?. Current Urology Reports 6:5, pages 319-321.
Crossref
Crossref
Jean Hay-Smith, Gaye Ellis & G Peter Herbison. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Fiona McCrimmon. (2005) The management of the overactive bladder. Practice Nursing 16:7, pages 325-328.
Crossref
Crossref
V. Nitti & S. Taneja. (2005) Overactive bladder: achieving a differential diagnosis from other lower urinary tract conditions. International Journal of Clinical Practice 59:7, pages 825-830.
Crossref
Crossref
Paul Taylor. (2005) Pharmacologic Management of Overactive Bladder. Journal of Wound, Ostomy and Continence Nursing 32, pages S16-S24.
Crossref
Crossref
Theodore Darkow, Christina L. Fontes & Todd E. Williamson. (2005) Costs Associated with the Management of Overactive Bladder and Related Comorbidities. Pharmacotherapy 25:4, pages 511-519.
Crossref
Crossref
Denis Getsios, Wissam El-Hadi, Ingrid Caro & J Jaime Caro. (2005) Pharmacological Management of Overactive Bladder. PharmacoEconomics 23:10, pages 995-1006.
Crossref
Crossref
W Andre Silva. (2005) Pharmacologic Management of Incontinence and Voiding Dysfunction. Journal of Pelvic Medicine and Surgery 11:1, pages 1-37.
Crossref
Crossref
M. Oelke, J. J. de la Rosette, M. C. Michel & U. Jonas. (2005) Medikamentöse Therapie der HarninkontinenzMedical therapy of urinary incontinence. Der Internist 46:1, pages 75-82.
Crossref
Crossref
V. Grünewald. 2005. Pharmakotherapie in der Urologie. Pharmakotherapie in der Urologie
283
311
.
C. Deppe, C. Dannecker, A. Strauss & H. Hepp. (2016) Medikamentöse Therapie der HarninkontinenzPharmaceutical treatment of urinary incontinence. Der Gynäkologe 37:11, pages 1017-1024.
Crossref
Crossref
Mario Cornacchione & Thomas J. Cali. (2004) Review of Urologic Problems in Senior Care: From Urinary Retention to Overactive BladderCLINICAL REVIEW COMMON UROLOGIC ISSUES IN LONG-TERM CARECLINICAL REVIEW INDIVIDUALIZING CARE FOR THE SENIOR WITH UROLOGIC PROBLEMS. The Consultant Pharmacist 19:0, pages 1-21.
Crossref
Crossref
Joseph G. Ouslander. (2004) Management of Overactive Bladder. New England Journal of Medicine 350:8, pages 786-799.
Crossref
Crossref
Susan J Keam & Caroline M Perry. (2004) Management of Overactive Bladder. Disease Management & Health Outcomes 12:2, pages 121-142.
Crossref
Crossref
D Getsios, J J Caro, K J Ishak, W El-Hadi, K Payne, M O??Connel, D Albrecht, W Feng & D Dubois. (2004) Oxybutynin Extended Release and Tolterodine Immediate Release. Clinical Drug Investigation 24:2, pages 81-88.
Crossref
Crossref
Dyfrig A Hughes & Dominique Dubois. (2004) Cost-Effectiveness Analysis of Extended-Release Formulations of Oxybutynin and Tolterodine for the Management of Urge Incontinence. PharmacoEconomics 22:16, pages 1047-1059.
Crossref
Crossref
Alan D Garely & Lara Burrows. (2004) Benefit-Risk Assessment of Tolterodine in the Treatment of Overactive Bladder in Adults. Drug Safety 27:13, pages 1043-1057.
Crossref
Crossref
Y. Homma, J.S. Paick, J.G. Lee & K. Kawabe. (2003) Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU International 92:7, pages 741-747.
Crossref
Crossref
Melissa E. Huggins, Narender N. Bhatia & Donald R. Ostergard. (2003) Urinary incontinence: newer pharmacotherapeutic trends. Current Opinion in Obstetrics and Gynecology 15:5, pages 419-427.
Crossref
Crossref